Clinical Trials Logo

Filter by:
NCT ID: NCT02753699 Completed - Clinical trials for Hepatitis C, Chronic

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Start date: December 2011
Phase: Phase 3
Study type: Interventional

Follow-up for durability of sustained virologic response, changes in liver function and safety in patients with SVR24 in feeder studies

NCT ID: NCT02753569 Completed - Cancer Clinical Trials

Imaging NSCLC Treatment Response to Immunotherapy

Start date: May 31, 2016
Phase:
Study type: Observational

This feasibility study will aim to assess the potential for functional imaging biomarkers (18FDG PET-CT and DW-MRI) to differentiate immunotherapy induced inflammation, indicative of response from non-response in patients with stage IV non-small cell lung cancer (NSCLC).

NCT ID: NCT02753530 Completed - Clinical trials for Inclusion Body Myositis

Study of Arimoclomol in Inclusion Body Myositis (IBM)

Start date: August 16, 2017
Phase: Phase 2
Study type: Interventional

Funding Source - FDA Office of Orphan Products Development (OOPD). The purpose of this study is to evaluate the safety and efficacy of the study drug, arimoclomol in IBM patients.

NCT ID: NCT02752958 Completed - Dentin Sensitivity Clinical Trials

Impact of Long Term Management of Dentine Hypersensitivity (DH) With a Daily Use Anti-sensitivity Toothpaste on the Quality of Life Related to Oral Health

Start date: May 23, 2016
Phase: N/A
Study type: Interventional

This multicentre, non-comparative design study will monitor the impact of long term management of DH with daily use of a sensitivity toothpaste on the quality of life of a population of sensitivity sufferers. Changes in oral health related quality of life will be monitored using the Dentine Hypersensitivity Experience Questionnaire (DHEQ). The study will be conducted in participants in good general health, with pre-existing self-reported and clinically diagnosed tooth sensitivity at screening.

NCT ID: NCT02752945 Completed - Depression Clinical Trials

Feasibility Trial of a One-day CBT Workshop ("DISCOVER") for 15-18 Year Olds With Anxiety and/or Depression in Clinics

Start date: April 2016
Phase: N/A
Study type: Interventional

This is a feasibility trial designed to test the feasibility and acceptability of a one-day Cognitive Behavioural Therapy (CBT) workshop intervention ("DISCOVER") for young people aged between 15-18 years, who are on local child and adolescent mental health services (CAMHS) waiting lists, awaiting treatment for difficulties with anxiety and/or depression. Participants will be randomised to receive either the DISCOVER workshop (in addition usual care) or to continue usual care.

NCT ID: NCT02752919 Completed - Healthy Clinical Trials

Study of Galunisertib in Healthy Participants

Start date: April 2016
Phase: Phase 1
Study type: Interventional

The study involves a single dose of galunisertib taken by mouth by Japanese participants and non-Japanese participants. The study will evaluate the relationship between the effect of the study drug on the electrical activity of the heart, as measured by electrocardiogram (ECG) and how much of the study drug gets into the blood stream and how long it takes the body to remove it. Ths study will last about 42 days for each participant.

NCT ID: NCT02752776 Completed - Plaque Psoriasis Clinical Trials

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

PROSE
Start date: March 17, 2016
Phase: Phase 4
Study type: Interventional

Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.

NCT ID: NCT02752204 Completed - Clinical trials for Diffuse Large B-Cell Lymphoma

An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

TORCH
Start date: October 2015
Phase: Phase 2
Study type: Interventional

The aim of this clinical trial is to see if the drug called AZD2014 is effective and safe to use to treat patients with relapsed or refractory Diffuse Large BCell Lymphoma (DLBCL). The trial will also be looking at combining the antibody (Rituximab) with the drug AZD2014 in a small number of patients to see if this can be done without increasing the toxicity. 36 patients will be recruited to the trial. 30 will receive AZD2014 alone and the remaining 6 will receive AZD2014 plus rituximab. AZD2014 will be given as a 125mg tablet that is to be taken twice a day for 2 days out of every 7 (i.e. on days 1 and 2 of every week). Rituximab will be given via IV infusion on day 1 of every 28 days (once every 4 weeks) for a maximum of 6 cycles.

NCT ID: NCT02752178 Completed - Clinical trials for Depressive Disorder, Major

Peripheral Immunomarker Validation in Treatment-resistant Depression

BIODEP
Start date: June 2015
Phase:
Study type: Observational

This is a study to characterise the role of inflammatory processes in depression. There is compelling evidence that inflammation is often associated with, and can cause, depression. It is currently less clear that antiinflammatory drugs have meaningful antidepressant effect. One of the goals is to identify the subset of depressed patients that is most likely to respond better to an antiinflammatory drug than to a conventional antidepressant. The investigators will therefore undertake a study of patients with a diagnosis of major depressive disorder including four groups: i) incompletely responsive patients who have demonstrated failure to respond consistently or completely to standard treatment, ii) those who have responded well to treatment and are not currently depressed, iii) untreated patients who are currently depressed, iv) healthy volunteers with no history of depression. Participants will undergo a clinical assessment, an interview with a trained member of the research team and will complete self-rated questionnaires. Investigators will collect blood and saliva samples to measure certain immune markers. They will also perform magnetic resonance imaging (MRI) scans to look for MRI markers in the brain and investigate brain inflammation in a subsample of these patients using positron emission topography (PET) and cerebrospinal fluid (CSF) sampling (also called lumbar puncture).

NCT ID: NCT02752074 Completed - Melanoma Clinical Trials

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Start date: June 21, 2016
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma